Princeton, New Jersey, United States, March 2026 — Paul Kotulka has stepped into a new role at Bristol Myers Squibb as Vice President, Fusion AI & Portfolio. Based in Princeton in an on-site capacity, he moves into the position after serving as Vice President of Global Business Operations, bringing deep experience across enterprise transformation, strategic alliances, M&A, governance, and operational excellence within global product development and supply.
In his recent journey at Bristol Myers Squibb, Paul Kotulka served as Vice President of Global Business Operations (April 2025 to March 2026), where he oversaw five divisional business functions—M&A, alliances, business continuity, integrated risk, and business process execution—supporting enterprise transformation and operational excellence across Global Product Development & Supply. His responsibilities included advancing strategic network initiatives and value creation efforts, alongside governance and leadership responsibilities including chairing the GPS Extended Leadership Team.
Earlier, he served as Vice President, Strategic Partnerships (September 2024 to April 2025), where he focused on manufacturing and supply initiatives spanning M&A due diligence, post-merger integration, divestitures, strategic alliance management, and PMO excellence across pharmaceuticals, biologics, cell therapy, and radiopharmaceuticals. In this role, he also supported talent development and leadership readiness initiatives.
Before joining Bristol Myers Squibb, Paul Kotulka spent more than 16 years with Merck & Co., Inc., where he held progressive operations and supply leadership roles including Associate Director of Operations (internally known as Associate Director of Manufacturing Operations & Supply Chain), Senior Manufacturing Manager, and Senior Procurement Analyst focused on global procurement for oral solid dosage and packaging.
About Bristol Myers Squibb
Bristol Myers Squibb is a global biopharmaceutical company focused on transforming patients’ lives through science. The company works across therapeutic areas including oncology, hematology, immunology, cardiovascular disease, and fibrosis, and highlights the use of translational medicine and data analytics to better understand how to deliver the right medicine to the right patient at the right time. Through the Bristol Myers Squibb Foundation, the company also supports efforts to promote health equity and improve health outcomes for populations disproportionately affected by serious diseases.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
